PIM1 and neoplasm: Specifically, our results demonstrate that the recently developed pan-PIM inhibitor PIM44737,38 impairs the proliferation, viability and G1/S transition of cells with JAK/STAT pathway mutations postulating PIM447 as a potential therapeutic option against tumor cells bearing these alterations.